Clinical trial
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE)…
NCT00152971 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00152971 |
|---|---|
| Title | Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement |
| Official title | A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthroplasty, Replacement, Knee, Thromboembolism |
| Intervention type | Drug |
| Interventions | Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion, Dabigatran Dose 2 - day 1, Enoxaparin |
| Enrollment | 2,615 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | May 5, 2014 |
| Countries | Canada, Mexico, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: